- Collaboration Increases Patient Access to the
CyberKnife® and TomoTherapy® Systems
SUNNYVALE, California,
Oct. 31, 2014 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY) today announced a long-term
collaboration with Lausanne University Hospital, Switzerland covering the CyberKnife® and
TomoTherapy® Systems. The alliance is based on a mutual commitment
to ongoing research in radiation oncology and the development of
innovative treatments that improve the quality of life for cancer
patients.
At Lausanne University Hospital, patients will now have access
to the newest CyberKnife and TomoTherapy Systems on the market.
Healthcare professionals may also gain exposure to both systems
through peer-to-peer training and education at the hospital. In
addition, the two respected organizations intend to collaborate on
clinical development and ongoing product innovations, benefiting
both healthcare professionals and their patients.
Further information on the systems is available at:
http://www.accuray.com/solutions/treatment-delivery/cyberknife-treatment-delivery/m6-series
http://www.accuray.com/solutions/treatment-delivery/tomotherapy-treatment-delivery/h-series
"Accuray continuously strives to provide clinicians and their
patients with radiation treatment options that deliver superior
tumor control and minimal side effects," said Lionel Hadjadjeba,
SVP International Business & GM Accuray International. "The
collaboration with Lausanne University Hospital will enable us to
benefit from a group of extremely experienced and skilled
clinicians and physicians, and accelerate clinical and product
development opportunities that may enhance quality of care."
Lausanne University Hospital is a renowned academic hospital
featuring an advanced oncology department and a strong team of
clinicians and medical physicists lead by Prof. Pierre-Francois
Leyvraz, General Manager, Lausanne University Hospital, Lausanne,
Switzerland. Its technical
platform is equipped with, among others, the TomoTherapy H™
Series recently upgraded with VoLO™ and TomoEDGE™, and the
CyberKnife M6™ System. The hospital is viewed as a leader in
medical care, research and training within the European community.
Further information about the hospital is available at:
http://www.chuv.ch/radio-oncologie/rth_home/rth-patients-et-familles/rth-patients-radiotherapie.htm.
"We view Accuray as a 'partner of choice' and believe our
collaboration will further our mission to pioneer medical advances
in the field of radiation oncology that are recognized by
clinicians around the world," said Prof. Pierre-Francois Leyvraz,
General Manager, Lausanne University Hospital, Lausanne,
Switzerland. "We're pleased with
the agreement because it provides us with the opportunity to have a
meaningful impact on the next generation of radiation oncology
treatments."
About the CyberKnife® and TomoTherapy® Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series
treatment solutions cover the entire spectrum of radiation therapy
needs. The CyberKnife M6 Series enables precise, high-quality, dose
distributions to be confidently delivered to the patient with
extreme accuracy over a minimum number of treatments, reducing side
effects and preserving patients' quality of life. The CyberKnife
System is the only robotic full-body radiosurgery system available
today. The TomoTherapy H Series efficiently enables physicians to
customize treatment plans for the entire range of radiation therapy
patients and disease types. Its innovative design enables treatment
plans to be delivered with integrated, daily CT image guidance,
enhancing accuracy and delivering highly precise,
intensity-modulated radiation for optimal sparing of healthy tissue
and critical structures.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to the expected benefits and
results of Accuray's relationship with Lausanne University
Hospital, including but not limited to clinical and product
development opportunities, and Accuray's leadership position in
radiation oncology innovation and technologies. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially from expectations, including
but not limited to the risks detailed under the heading "Risk
Factors" in the company's report on Form 10-K, filed on
August 29, 2014, and the company's
other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
RELATED LINKS
http://www.accuray.com